GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox. According to Globaldata, it is involved in 1 clinical trial, which was completed. GlobalData uses proprietary data and analytics to provide a complete picture of GSK-4178116As valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GSK-4178116A is expected to reach an annual total of $89 mn by 2039 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GSK-4178116A Overview
GSK-4178116A is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous route.
GSK Overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSKs vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP30,328 million for the fiscal year ended December 2023 (FY2023), an increase of 3.4% over FY2022. In FY2023, the companys operating margin was 22.2%, compared to an operating margin of 21.9% in FY2022. In FY2023, the company recorded a net margin of 16.2%, compared to a net margin of 51% in FY2022.
The company reported revenues of GBP7,363 million for the first quarter ended March 2024, a decrease of 8.6% over the previous quarter.
For a complete picture of GSK-4178116As valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.